Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
The prevalence, intensity, safety, and efficacy of oral anticoagulation (OAC) in addition to dual antiplatelet therapy (DAPT) in “real-world” patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not yet been fully evaluated. In the Coronary REvascularization Demonstrating Outcome Study in Kyoto registry cohort-2, a total of 1,057 patients with AF (8.3%) were identified among 12,716 patients undergoing first PCI. Cumulative 5-year incidence of stroke was higher in patients with AF than in no-AF patients (12.8% vs 5.8%, p
Source: The American Journal of Cardiology - April 25, 2014 Category: Cardiology Authors: Koji Goto, Kentaro Nakai, Satoshi Shizuta, Takeshi Morimoto, Hiroki Shiomi, Masahiro Natsuaki, Mitsuhiko Yahata, Chihiro Ota, Koh Ono, Takeru Makiyama, Yoshihisa Nakagawa, Yutaka Furukawa, Kazushige Kadota, Yoshiki Takatsu, Takashi Tamura, Akinori Takizaw Tags: Arrhythmias and Conduction Disturbances Source Type: research
Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation
In conclusion, our study suggests that patients treated with rivaroxaban during periprocedural catheter ablation have similar rates of thromboembolic events and major hemorrhage. Similar results were seen in direct comparisons between dabigatran and rivaroxaban.
Source: The American Journal of Cardiology - June 9, 2014 Category: Cardiology Authors: Madan Raj Aryal, Anene Ukaigwe, Anil Pandit, Paras Karmacharya, Rajesh Pradhan, Naba Raj Mainali, Ranjan Pathak, Leena Jalota, Yashoda Bhandari, Anthony Donato Tags: Arrhythmias and Conduction Disturbances Source Type: research
Optimal Blood Pressure in Patients With Atrial Fibrillation (from the AFFIRM Trial)
Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major...
Source: The American Journal of Cardiology - June 20, 2014 Category: Cardiology Authors: Apurva O. Badheka, Nileshkumar J. Patel, Peeyush M. Grover, Neeraj Shah, Nilay Patel, Vikas Singh, Abhishek J. Deshmukh, Kathan Mehta, Ankit Chothani, Ghanshyambhai T. Savani, Shilpkumar Arora, Ankit Rathod, George R. Marzouka, James Lafferty, Jawahar L. Tags: Systemic Hypertension Source Type: research
Coronary Artery Calcium and Risk of Atrial Fibrillation (From the Multi-Ethnic Study of Atherosclerosis)
Calcified coronary arteries are associated with the development of cardiovascular disease and stroke. It is currently unknown whether coronary artery calcium (CAC) is associated with an increased risk of atrial fibrillation (AF). We addressed this question in 6,641 participants (mean age 62 ± 10; 53% women; 62% non-whites) from the Multi-Ethnic Study of Atherosclerosis (MESA) who were free of baseline clinical cardiovascular disease and AF. CAC measurements were assessed by cardiac computed tomography (CT) at study baseline.
Source: The American Journal of Cardiology - September 14, 2014 Category: Cardiology Authors: Wesley T. O’Neal, Jimmy T. Efird, Farah Z. Dawood, Joseph Yeboah, Alvaro Alonso, Susan R. Heckbert, Elsayed Z. Soliman Source Type: research
Relation of -Dimer and Troponin I in Patients With New-Onset Atrial Fibrillation
In the report by Parashar et al,1 it was recently concluded that cardiospecific troponin was not independently associated with new-onset atrial fibrillation (AF) after acute myocardial infarction. Several lines of evidence now attest that the concentrations of cardiospecific troponins2 and d-dimer3 are increased in patients with AF and that their values are significantly associated with a worse prognosis including stroke, death, and thromboembolic events. Nevertheless, no information is available on the relation between these 2 biomarkers in patients with new-onset AF.
Source: The American Journal of Cardiology - July 28, 2014 Category: Cardiology Authors: Gianfranco Cervellin, Laura Bonfanti, Alessandra Picanza, Giuseppe Lippi Tags: Readers' Comments Source Type: research
Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias under Continuous Anticoagulation with Apixaban versus Phenprocoumon
Apixaban is increasingly used for stroke prevention in patients with atrial fibrillation (AF). Data about the safety of left atrial radiofrequency ablation procedures under continuous apixaban therapy are lacking. We performed a matched cohort study of patients undergoing LA ablation procedures for AF or left atrial flutter. For each patient on apixaban, two patients on phenprocoumon were matched by age, sex, and type of arrhythmia. The primary safety endpoint was a composite of bleeding, thromboembolic events and death.
Source: The American Journal of Cardiology - October 11, 2014 Category: Cardiology Authors: Bernhard M. Kaess, Sonia Ammar, Tilko Reents, Roger Dillier, Carsten Lennerz, Verena Semmler, Christian Grebmer, Felix Bourier, Alessandra Buiatti, Christof Kolb, Isabel Deisenhofer, Gabriele Hessling Source Type: research
Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN™ Left Atrial Appendage Closure Therapy
The WATCHMAN (Boston Scientific Corp, Maple Grove, MN) left atrial appendage closure (LAAC) technology is a percutaneously delivered permanent cardiac implant placed in the LAA. This device is designed to reduce the risk of stroke and systemic embolism in warfarin-eligible patients with non-valvular atrial fibrillation. The first circulatory system device panel reviewed the Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF) study in 2009, and a “Not Approvable” letter was issued by the US Food and Drug Administration (FDA) based on safety concerns.
Source: The American Journal of Cardiology - November 11, 2014 Category: Cardiology Authors: Ron Waksman, Lakshmana K. Pendyala Source Type: research
Prevalence of Intracardiac Thrombi under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran, Rivaroxaban) and Bridging Therapy in Patients with Atrial Fibrillation and Flutter
Direct oral anticoagulants (DOACs) are effective for stroke prevention in non-valvular atrial fibrillation. Cardioversion (CV) is frequently performed in patients with atrial fibrillation or flutter (AF). To further explore the safety profile of DOACs in the context of CV we sought to assess the prevalence of intracardiac thrombi under DOAC therapy in comparison to treatment with vitamin K antagonists. A total of 672 transesophageal echocardiograms (TEE) performed on 643 patients with a history of non-valvular AF were analyzed.
Source: The American Journal of Cardiology - December 17, 2014 Category: Cardiology Authors: Maura M. Zylla, Mara Pohlmeier, Alexander Hess, Derliz Mereles, Meinhard Kieser, Thomas Bruckner, Eberhard Scholz, Edgar Zitron, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas Source Type: research
Overview of the Food and Drug Administration Circulatory System Devices Panel Meetings on WATCHMAN Left Atrial Appendage Closure Therapy
The WATCHMAN left atrial appendage closure (LAAC) technology is a percutaneously delivered permanent cardiac implant placed in the LAA. This device is designed to reduce the risk of stroke and systemic embolism in warfarin-eligible patients with nonvalvular atrial fibrillation. The first circulatory system device panel reviewed the Embolic Protection in Patients With Atrial Fibrillation (PROTECT AF) study in 2009, and a “not approvable” letter was issued by the US Food and Drug Administration (FDA) based on safety concerns.
Source: The American Journal of Cardiology - November 11, 2014 Category: Cardiology Authors: Ron Waksman, Lakshmana K. Pendyala Tags: Review Source Type: research
Prevalence of Intracardiac Thrombi Under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran and Rivaroxaban), and Bridging Therapy in Patients With Atrial Fibrillation and Flutter
Direct oral anticoagulants (DOACs) are effective for stroke prevention in nonvalvular atrial fibrillation (AF). Cardioversion (CV) is frequently performed in patients with AF or flutter. To further explore the safety profile of DOACs in the context of CV, we sought to assess the prevalence of intracardiac thrombi under DOAC therapy in comparison with treatment with vitamin K antagonists. A total of 672 transesophageal echocardiograms performed in 643 patients with a history of nonvalvular AF were analyzed.
Source: The American Journal of Cardiology - December 17, 2014 Category: Cardiology Authors: Maura M. Zylla, Mara Pohlmeier, Alexander Hess, Derliz Mereles, Meinhard Kieser, Thomas Bruckner, Eberhard Scholz, Edgar Zitron, Patrick A. Schweizer, Hugo A. Katus, Dierk Thomas Tags: Arrhythmias and Conduction Disturbances Source Type: research
Antithrombotic Strategies and Outcomes in Acute Coronary Syndrome with Atrial Fibrillation
Atrial fibrillation (AF) frequently occurs with acute coronary syndromes (ACS) and adds complexity to the selection of an appropriate antithrombotic strategy. We determined whether associations of antithrombotic treatment with bleeding, stroke, and death differ between ACS patients with and without AF. Olmsted County, MN residents hospitalized with incident ACS during 2005-2010 were classified according to the presence or absence of AF either prior to or during the index ACS hospitalization. Antithrombotic strategy at discharge was categorized as double/triple agents vs.
Source: The American Journal of Cardiology - January 31, 2015 Category: Cardiology Authors: Alanna M. Chamberlain, Bernard J. Gersh, Roger M. Mills, Winslow Klaskala, Alvaro Alonso, Susan A. Weston, Véronique L. Roger Source Type: research
Factors Driving Anticoagulant Selection in Patients with Atrial Fibrillation in the United States
With the introduction of novel oral anticoagulants (NOACs), the factors driving anticoagulant selection in atrial fibrillation (AF) in real-world practice are unclear. The goal was to examine whether and to what extent utilization has been driven by predictions of stroke risk (treatment benefit), bleeding risk (treatment harm), or prescription benefits’ coverage. We extracted a cohort of non-valvular AF patients initiating anticoagulation from Oct 2010-Dec 2012 from a large US database of commercial and Medicare supplement claims.
Source: The American Journal of Cardiology - February 2, 2015 Category: Cardiology Authors: Julie C. Lauffenburger, Joel F. Farley, Anil K. Gehi, Denise H. Rhoney, M. Alan Brookhart, Gang Fang Source Type: research
PP-096 A Newly Defined CHA2DS2-VASc-CAC Score and Using Prediction of Coronary Artery Disease Severity by Computed Tomography
CHA2DS2-VASc scores are validated tools for assessing stroke risk in patients with atrial fibrillation (AF). It is known that traditional risk factors for coronary artery disease and CHAD2 VASc score's parameters are similar.We formulated the CHA2DS2-VASc-CAC score comprising coronary calcium score(CACS) in addition to the components of the CHA2DS2-VASc score and male instead of female gender as We evaluated multivariable risk assessment tools to identify those at high risk of severe CAD in patients who underwent computed tomography(CT).
Source: The American Journal of Cardiology - March 12, 2015 Category: Cardiology Authors: Bora Demircelik, Mahmut Gunes, Muhammed Kemal Yahyalar, Meltem Altinsoy, Fadime Bozduman, Ozgul Malcok Gurel, Beyhan Eryonucu Tags: Poster Abstract Source Type: research
PP-093 P Wave Dispersion is not Related with Systolic Blood Pressure Variability
Systolic Blood pressure variability (SBPV) is a novel indicator of stroke. P wave dispersion (PWD) is a well known parameter obtained from routine ECG, which is an indicator of interatrial and intraatrial conduction abnormalities. Higher PWD values is linked to higher risk of atrial fibrillation in many prospective studies. The aim of our study is to measure PWD from routine ECG tests of hypertensive patients and to determine its relation with SBPV.
Source: The American Journal of Cardiology - March 12, 2015 Category: Cardiology Authors: Muhammed Necati Murat Aksoy, Harun Kilic, Mehmet Bulent Vatan, Direnc Yilmaz, Ramazan Akdemir, Huseyin Gunduz Tags: Poster Abstract Source Type: research
OP-137 Does Electrocardiographic Diastolic Index Predict Asymptomatic Atrial Fibrillation in Patients with Dual-chamber Pacemaker?
Asymptomatic atrial fibrillation episodes detected by pacemaker is known to increase the risk of systemic embolism and stroke by 2-3 times in patients with dual-chamber pacemaker. Atrial high-rate episodes presence together with duration of episodes is also an important indicator of adverse events. The studies have shown the relationship between the electrocardiographic diastolic index and the development of diastolic dysfunction. The aim of our study was to show the relationship between the ECG index (Tend-P/[PQxAge]) and atrial fibrillation in patients with dual-chamber pacemaker.
Source: The American Journal of Cardiology - March 12, 2015 Category: Cardiology Authors: Ahmet Ilker Tekkesin, Emrah Bozbeyoglu, Ozlem Yildirimturk, Ceyhan Turkkan, Yasin Cakilli, Ahmet Murat, Mert Ilker Hayiroglu, Ahmet Taha Alper Tags: Oral Abstract Source Type: research
